{"id":942019,"date":"2026-03-04T10:36:06","date_gmt":"2026-03-04T15:36:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/"},"modified":"2026-03-04T10:36:06","modified_gmt":"2026-03-04T15:36:06","slug":"upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/","title":{"rendered":"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong>Ultragenyx Pharmaceuticals Investors With Significant Losses Are Encouraged To Contact Faruqi &amp; Faruqi, LLP Securities Litigation Partner <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ucVCzayli8aFHEYAv95PgFt-GeuZ5zH6TGQABwWZy6FsVQ91oLMS7T6Nm3yjGk8tNDdOonJvJX7rHnDVvTw9iCwfQmBRlP1bMy_hvG0kolBoRer15IqNUZ6p6TRhnZ7xNwX-0ZwbvweMw8bcG5-icA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>James (Josh) Wilson<\/strong><br \/>\n        <\/a><br \/>\n        <strong>\u00a0To Discuss Their Legal Rights<\/strong>\n      <\/p>\n<p>\n        <strong>If you purchased or acquired securities in <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BS3OUi-L8AR0zc2sYVArGrbHJFukLbU_P6YKFherAnMtLHORKomlouxduEWn_K9iibcfJf4JMZ27QXombIWuZnnyLxF3sk-LL5Bz9Vhq27w=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Ultragenyx<\/strong><br \/>\n        <\/a><br \/>\n        <strong> between August 3, 2023 and December 26, 2025 <\/strong>and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner <strong>Josh Wilson directly <\/strong>at <strong>877-247-4292 <\/strong>or <strong>212-983-9330 (Ext. 1310)<\/strong>.<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gRqdZexiwtZM2e0TQ3EGYFogw9X6B7-arEOc4-7D-amPudnW-pvStJ3nfZvstsB4WtnjU0bgo0RZB13Q-lUsR1bYdTLL4C2-8FJwRt8Eei6dkohLBcN-2QJx05UJXH3xAvk3-GfIQSfoXw8niZFt7w==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>[You may also click here for additional information]<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p align=\"center\">\n        \n      <\/p>\n<p>NEW YORK, March  04, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0KtEt9SlrXysj11fGVVfG8vSD82CxA7YJQpc5e4vpbohehRE8-Wts3IwIs0hC2ar2ib1kPf1_ym9DEauQ9oy--s5tNpsHFZzBvgcbt6EfEA=\" rel=\"nofollow\" target=\"_blank\">Faruqi &amp; Faruqi, LLP<\/a>, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (\u201cUltragenyx\u201d or the \u201cCompany\u201d) (NASDAQ: RARE) and reminds investors of the <strong>April 6, 2026 deadline<\/strong> to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.<\/p>\n<p>Faruqi &amp; Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MwxJvNJq7iEeEmn8nOzkgDsnNNMoNywT7wHOqoqxSRHOgWqcDMESdDzEKQBC3wgllXOWmBVAyhxqlBdU28QDn5eYMj9V_LQ0xYwVDRVBMR0=\" rel=\"nofollow\" target=\"_blank\">www.faruqilaw.com<\/a>.<\/p>\n<p>As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and\/or misleading statements and\/or failing to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta (\u201cOI\u201d), while also minimizing risk that patients in Ultragenyx\u2019 Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate (\u201cAFR\u201d), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx\u2019 optimism in the Phase III Orbit study\u2019s results and interim analysis benchmark were misplaced because Ultragenyx failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and thus had not ruled out that the reduction in AFR from that study could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment.<\/p>\n<p>On July 9, 2025, Ultragenyx revealed that the Phase III Orbit study failed to achieve statistical significance for the second interim analysis and that Phase III Orbit and Cosmic studies would now be \u201cprogressing toward final analysis.\u201d<\/p>\n<p>On this news, the price of Ultragenyx stock fell more than 25%, according to the complaint.<\/p>\n<p>Then, on December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not \u201cachieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.\u201d Ultragenyx allegedly attributed the study failure to a \u201clow fracture rate in the placebo group\u201d of Orbit and a trend that fell shy of statistical significance in Cosmic.<\/p>\n<p>On this news, the price of Ultragenyx stock fell more than 42%, according to the complaint.<\/p>\n<p>The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.\u00a0\u00a0<\/p>\n<p>Faruqi &amp; Faruqi, LLP also encourages anyone with information regarding Ultragenyx\u2019s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.<\/p>\n<p>To learn more about the <strong>Ultragenyx Pharmaceutical<\/strong> class action, go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MwxJvNJq7iEeEmn8nOzkgN0JcE4x0XSFH-HTbDpdvTZAya5BF2aUHOnqzNYPdoTpmFfEdYheSAem03ptPkYAHpLeFzeM-zR5UMPK18sGNFU=\" rel=\"nofollow\" target=\"_blank\"><strong>www.faruqilaw.com\/RARE<\/strong><\/a> or <strong>call<\/strong> Faruqi &amp; Faruqi partner <strong>Josh Wilson directly <\/strong>at <strong>877-247-4292 <\/strong>or <strong>212-983-9330 (Ext. 1310)<\/strong>.<\/p>\n<p>Follow us for updates on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E3T5tAa07LGNaiqepDaAhV4eiJZ9QxfEvq0xfHJs7IwDo1LCqB-uKo6dQ2R4qAH79GwWNKxzZziJLOXbdQcnFl8h7ytZlTOh2Sx8NVhbly_rhGc8zj5xHYrO9NbjqFFT\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_W6jxfRE44sfhrlPNnlgd-4OukhJWurPbNMo_wXB45748TXdtWJBJg8sdcP6mtlfny4HPrG4rYUkvzJmEvLIsg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, or on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=acVXruy2nmUf7NXeFv7yCfrWmYtQf9IXYIzkRiH6uRUFXqv1go0zHDtnQFtSt2q2tQSQEGQOBFAd3rBuLEkhuAOl0o8LnQXsd3ar_Xy5kgQ=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>Attorney Advertising. The law firm responsible for this advertisement is Faruqi &amp; Faruqi, LLP (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MwxJvNJq7iEeEmn8nOzkgNPjXzxdH6jRbfqRbDI-0mM83ZJZSVEynLFrxGtaewzqBwMTbKgubd8n5IBXrqNb2p6KiwsQMU5kmVvSWCBPxOM=\" rel=\"nofollow\" target=\"_blank\">www.faruqilaw.com<\/a>). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.<\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hPNOj_-nshsGqu9lsrUVkeITSnbJwSUKP154Ee8cMOuzsBXDPAI-y7nSviYRtrX3QOou3hWcFd9vmvMZXG6IrIn1VXn5N17L6PyZlJZAff-zPk-lnAZ40ughFxhSJQH_ZOubf7IpNWCZTidmRrt3USjPiT_gGy6nrjRwZryp9TPoVqOOeGsoi5lzZE9wSBxWXVL2thFyDx8Udrho6gy746r9HP2bVTBvg360GIXhnHP7SmGWxkHPFYSZPLYiWHOUg1tqvyn8tUl0ho4SoXVdWA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/7f60c456-51b6-4096-a862-d5d3beda6cc5<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Yzg1OGQyMTYtNjY5YS00NDVlLTljNTUtMmUyZWQ3YzUzOTg1LTEwMjkyMDktMjAyNi0wMy0wNC1lbg==\/tiny\/Faruqi-Faruqi-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ultragenyx Pharmaceuticals Investors With Significant Losses Are Encouraged To Contact Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson \u00a0To Discuss Their Legal Rights If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) &#8212; Faruqi &amp; Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (\u201cUltragenyx\u201d or the \u201cCompany\u201d) (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942019","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline - Furuqi &amp; Furuqi LLP - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline - Furuqi &amp; Furuqi LLP - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ultragenyx Pharmaceuticals Investors With Significant Losses Are Encouraged To Contact Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson \u00a0To Discuss Their Legal Rights If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) &#8212; Faruqi &amp; Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (\u201cUltragenyx\u201d or the \u201cCompany\u201d) (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in &hellip; Continue reading &quot;UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T15:36:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP\",\"datePublished\":\"2026-03-04T15:36:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/\"},\"wordCount\":719,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/\",\"name\":\"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline - Furuqi &amp; Furuqi LLP - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=\",\"datePublished\":\"2026-03-04T15:36:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline - Furuqi &amp; Furuqi LLP - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/","og_locale":"en_US","og_type":"article","og_title":"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline - Furuqi &amp; Furuqi LLP - Market Newsdesk","og_description":"Ultragenyx Pharmaceuticals Investors With Significant Losses Are Encouraged To Contact Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson \u00a0To Discuss Their Legal Rights If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) &#8212; Faruqi &amp; Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (\u201cUltragenyx\u201d or the \u201cCompany\u201d) (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in &hellip; Continue reading \"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-04T15:36:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP","datePublished":"2026-03-04T15:36:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/"},"wordCount":719,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/","name":"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline - Furuqi &amp; Furuqi LLP - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=","datePublished":"2026-03-04T15:36:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTM0MiM3NDY2MTU3IzIwMTc2MzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/upcoming-deadline-ultragenyx-pharmaceutical-inc-rare-securities-fraud-class-action-april-6-2026-lead-plaintiff-deadline-furuqi-furuqi-llp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action \u2013 April 6, 2026 Lead Plaintiff Deadline &#8211; Furuqi &amp; Furuqi LLP"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942019"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942019\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}